Long acting GLP-1 receptor agonist (injectable)
Ecnoglutide 0.6 mg injection once weekly
ECNO_SC_0p6MG_QW
Related
- All doses pooled: Ecnoglutide injection
- Ecnoglutide 1.2 mg injection once weekly
- Ecnoglutide 0.2 mg injection once weekly
- Ecnoglutide 0.4 mg injection once weekly
- Ecnoglutide 0.1 mg injection
- Ecnoglutide flexible dose injection
- Ecnoglutide flexible dose injection
- Ecnoglutide flexible dose injection
- Ecnoglutide 0.6 mg injection
- Ecnoglutide 0.8 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.00 (-2.47 to 0.90) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.10 (-1.49 to -0.70) | 0.52 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.59 (-5.16 to 1.97) | 0.63 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 6.16 (1.04 to 27.04) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.50 (0.18 to 12.54) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.57 (0.01 to 38.40) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.56 (0.01 to 36.57) | 0.57 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.47 (-8.80 to 4.29) | 0.60 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 4.52 (1.28 to 14.65) | 0.77 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 4.75 (0.88 to 31.06) | 0.66 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.59 (0.09 to 3.05) | 0.65 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.18 (0.07 to 16.92) | 0.54 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.93 (0.26 to 2.89) | 0.75 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 5.85 (2.14 to 17.73) | 0.08 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.72 (0.05 to 12.76) | 0.50 |